“Sustained and Improved Efficacy of Tildrakizumab from Week 28 to Week 52 in Treating Moderate-to-Severe Plaque Psoriasis”. SKIN The Journal of Cutaneous Medicine, vol. 2, no. S1, Feb. 2018, p. S22, https://doi.org/10.25251/skin.2.supp.22.